Evidence map›Paper›PMID 35056568›Full record

ArticleMicroorganisms2022

Bugs on Drugs: A

Bram Van den Bergh

Abstract read
In one paragraph

Article in Microorganisms, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Surviving Colonies ofAntibiotics (Basel, Switzerland) · 2025
    Article
  3. Antimicrobial Effect of Diphenyl Ditelluride (PhTe)Indian journal of microbiology · 2024
    Article
  4. Article
  5. Frontiers in microbiology · 2024
    Review
  6. Microbiology spectrum · 2023
    Article
  7. microPublication biology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Bram Van den BerghDepartment of Entomology, Cornell University, Ithaca, NY 14853, USA.ORCID 0000-0003-4429-9780

Funding

Belgian American Educational Foundation 2016-E083European Molecular Biology Organization ALTF 344-2017Research Foundation - Flanders 12O1917NResearch Foundation - Flanders 12O1922NResearch Foundation - Flanders 1513120NResearch Foundation - Flanders V428917N
6 · The paper itself

Abstract

With an antibiotic crisis upon us, we need to boost antibiotic development and improve antibiotics' efficacy. Crucial is knowing how to efficiently kill bacteria, especially in more complex in vivo conditions. Indeed, many bacteria harbor antibiotic-tolerant persisters, variants that survive exposure to our most potent antibiotics and catalyze resistance development. However, persistence is often only studied in vitro as we lack flexible in vivo models. Here, I explored the potential of using

Indexed as

antibioticsantibiotic toleranceDrosophila melanogastergut microbiotahipAin vivopersistencepersister cells

Identifiers

PMID35056568
PMCPMC8780219

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.